COLORADO SPRINGS, CO – For the first time hemodiafiltration will be delivered to dialysis patients in the United States. DaVita Kidney Care, one of the leading kidney care providers, announced it will be delivering hemodiafiltration treatment to select patients in a Colorado Springs clinic. The trial is expected to last six months.
The most common treatment for patients suffering from kidney damage, disease, or failure is hemodialysis. Hemodiafiltration differs from dialysis in that it incorporates the existing dialysis processes, but includes additional steps to filter even larger toxin particles from the patient’s blood. European dialysis centers often practice hemodiafiltration, but this is the first time the treatment will be offered in the U.S.
Shaun Collard, Vice President of Clinical Operations at DaVita, commented, “At DaVita, we are always evaluating ways to improve patient outcomes and experience during dialysis treatments. We are excited to have the opportunity to be the first U.S. provider to evaluate this treatment.”
The main purpose of the six-month trial is to determine if hemodiafiltration provides better outcomes over traditional dialysis methods. Another important factor of the trial is to measure the impact on the patient’s quality of life with the new treatment.
While the benefits of hemodiafiltration are still unclear, this new study will be the first to shed light on any potential benefits. “We are constantly evaluating the efficacy of kidney care treatments and hemodiafiltration has shown potential benefits internationally,” said Dr. Robert Provenzano, M.D., FACP, and Vice President in DaVita’s Office of the Chief Medical Officer.